Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.

Academic Article

Abstract

  • UNLABELLED: We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. CLINICAL TRIALS REGISTRATION: NCT02073656.
  • Published In

    Keywords

  • HCV NS5B polymerase inhibitor, HCV/HIV coinfection, NS5A resistance, direct-acting antiviral agents, re-treatment, Adult, Aged, Antiviral Agents, Benzimidazoles, Coinfection, Drug Therapy, Combination, Fluorenes, HIV, HIV Infections, Hepacivirus, Hepatitis C, Chronic, Humans, Middle Aged, Recurrence, Ribavirin, Salvage Therapy, Sofosbuvir, Treatment Failure
  • Digital Object Identifier (doi)

    Author List

  • Cooper C; Naggie S; Saag M; Yang JC; Stamm LM; Dvory-Sobol H; Han L; Pang PS; McHutchison JG; Dieterich D
  • Start Page

  • 528
  • End Page

  • 531
  • Volume

  • 63
  • Issue

  • 4